Pirinixil

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414998

CAS#: 65089-17-0

Description: Pirinixil is a hypolipidemic low toxicity agent.

Chemical Structure

img
Pirinixil
CAS# 65089-17-0
Instruction

Theoretical Analysis

MedKoo Cat#: 414998
Name: Pirinixil
CAS#: 65089-17-0
Chemical Formula: C16H19ClN4O2S
Exact Mass: 366.09
Molecular Weight: 366.860
Elemental Analysis: C, 52.38; H, 5.22; Cl, 9.66; N, 15.27; O, 8.72; S, 8.74

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Pirinixil; CCRIS134; CCRIS-134; CCRIS 134; BR931; BR 931; BR-931

IUPAC/Chemical Name: 2-((4-Chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio)-N-(2-hydroxyethyl)acetamide

InChi Key: RZCKTPORLKUFGY-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H19ClN4O2S/c1-10-4-3-5-12(11(10)2)19-14-8-13(17)20-16(21-14)24-9-15(23)18-6-7-22/h3-5,8,22H,6-7,9H2,1-2H3,(H,18,23)(H,19,20,21)

SMILES Code: O=C(NCCO)CSC1=NC(NC2=CC=CC(C)=C2C)=CC(Cl)=N1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 366.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: D'Atri G, Gomarasca P, Galimberti E, Sirtori CR, Kritchevsky D. Clofibrate, pirinixil (BR 931) and WY-14,643 do not affect body cholesterol in Sprague- Dawley rats. Atherosclerosis. 1980 Nov;37(3):475-83. doi: 10.1016/0021-9150(80)90154-9. PMID: 7458993.

2: Kritchevsky D, Singer D, Klurfeld DM. Influence of hypocholesterolemic drugs on aortic cholesterol esterase in rabbits. Pharmacol Res Commun. 1984 Jun;16(6):525-31. doi: 10.1016/s0031-6989(84)80033-8. PMID: 6463093.

3: Lovati MR, De Marchi G. Plasma lipoprotein composition in cholesterol fed rabbits treated with pirinixil (BR 931), a new lipid lowering agent. Pharmacol Res Commun. 1981 Feb;13(2):133-9. doi: 10.1016/s0031-6989(81)80014-8. PMID: 7220573.

4: Najemnik C, Irsigler K, Sirtori CR. Pilot study of pirinixil (BR 931) in various forms of hyperlipoproteinemias. Pharmacol Res Commun. 1981 Sep;13(8):777-86. doi: 10.1016/s0031-6989(81)80096-3. PMID: 7027276.

5: Kritchevsky D, Klurfeld DM, Tepper SA, Mueller MA, Puglisi L, Sirtori CR. Increased plasma cholesterol and decreased body lipid levels in Wistar rats following pirinixil (BR 931) treatment. Pharmacol Res Commun. 1979 Jun;11(6):475-82. doi: 10.1016/s0031-6989(79)80019-3. PMID: 504321.

6: Simbula G, Pibiri M, Sanna L, Cossu C, Molotzu F, Columbano A, Ledda- Columbano GM. The peroxisome proliferator BR931 kills FaO cells by p53-dependent apoptosis. Life Sci. 2004 Jun 4;75(3):271-86. doi: 10.1016/j.lfs.2003.10.039. PMID: 15135649.

7: Shinozuka H, Abanobi SE, Lombardi B. Modulation of tumor promotion in liver carcinogenesis. Environ Health Perspect. 1983 Apr;50:163-8. doi: 10.1289/ehp.8350163. PMID: 6135607; PMCID: PMC1569229.

8: Eagon PK, Teepe AG, Elm MS, Tadic SD, Epley MJ, Beiler BE, Shinozuka H, Rao KN. Hepatic hyperplasia and cancer in rats: alterations in copper metabolism. Carcinogenesis. 1999 Jun;20(6):1091-6. doi: 10.1093/carcin/20.6.1091. PMID: 10357793.

9: Gupta C, Hattori A, Shinozuka H. Suppression of EGF binding in rat liver by the hypolipidemic peroxisome proliferators, 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio-(N-beta-hydroxyethyl)ac etamide and di(2-ethylhexyl)phthalate. Carcinogenesis. 1988 Jan;9(1):167-9. doi: 10.1093/carcin/9.1.167. PMID: 3257172.

10: Ohmura T, Ledda-Columbano GM, Piga R, Columbano A, Glemba J, Katyal SL, Locker J, Shinozuka H. Hepatocyte proliferation induced by a single dose of a peroxisome proliferator. Am J Pathol. 1996 Mar;148(3):815-24. PMID: 8774136; PMCID: PMC1861716.